Loading clinical trials...
Loading clinical trials...
Novel Biomarkers for Evaluation of Hemostasis and Inflammation in Liver Cirrhosis
Evaluating hemostasis in decompensated liver cirrhosis with novel hemostatic assays.
The rebalanced hemostasis in liver cirrhosis is vulnerable and patients are prone to both bleeding and thrombosis. There are today no gold standard for evaluating the hemostasis and we will evaluate novel methods for this.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
Yes
Karolinska University Hospital
Stockholm, Huddinge, Sweden
Start Date
December 2, 2022
Primary Completion Date
December 1, 2026
Completion Date
December 1, 2028
Last Updated
January 19, 2024
100
ESTIMATED participants
T-TAS
DIAGNOSTIC_TEST
Lead Sponsor
Region Stockholm
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions